Search results for "Highlights"


 
Results 31 - 40 of about 316 for "Highlights".

Highlights

Unintentional weight loss and weight loss in those with a body mass index already in the normal range were particularly associated with risk of pancreatic cancer among patients with recent-onset diabetes, a study found.
September 2020

Highlights

In a systematic review and meta-analysis, no difference was seen between high- and low-dose sodium-glucose cotransporter-2 (SGLT-2) inhibitors in overall safety or specific safety outcomes, other than a mild increased risk for adverse events with
September 2020

Trial finds improvement in HbA1c level with intensive periodontal treatment

They pointed out that almost 50% of patients with diabetes have severe periodontitis and that their findings “highlight the potential to improve metabolic control and possibly diabetes outcomes by addressing poor
November 2018

Oral semaglutide led to greater reductions in HbA1c, body weight than sitagliptin

The industry-funded PIONEER 3 trial randomized adults whose type 2 diabetes was uncontrolled with metformin, with or without sulfonylurea, to receive either oral sitagliptin (100 mg/d) or oral semaglutide (3, 7, or 14 mg/d).
April 2019

Insulin pump didn't improve glycemic control compared to training on injections

British patients with type 1 diabetes were enrolled in group training courses that taught flexible intensive insulin treatment and then randomized to an insulin pump or multiple daily injections and followed for two years.
April 2017

Weekly GLP-1 analogue associated with reduced MI, stroke risk, industry study finds

The trial of semaglutide included 3,297 patients with type 2 diabetes, 83% of whom had established cardiovascular disease, chronic kidney disease, or both.
October 2016

Highlights

Our analyses demonstrate the therapeutic potential of IF as a weight reduction strategy in [type 2 diabetes] and highlight the need for further research in this field,” the authors wrote.
January 2021

Liraglutide may offer high-risk patients protection from CV events, death, study finds

The Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial, which was funded by Novo Nordisk and the National Institutes of Health, randomized 9,340 patients ages 50 years and older to 1.8 mg of
July 2016

Highlights

A retrospective cohort study used electronic health record data from one health care system to assess postoperative mortality and readmission rates in adults who had major surgery.
May 2020

Highlights

A study of African-American, Hispanic, and Caucasian patients with type 1 and type 2 diabetes found that the most significant predictors of fracture risk varied by race and ethnicity.
April 2020

Result Page: Prev   1   2   3   4   5   6   7   8   9   10   Next